Sponsored by
It was reported in March 2024 that the METIS trial met its primary endpoint of time to intracranial progression for patients with brain metastases from non-small cell lung cancer (21.9 months in TTFields group vs 11.3 months in control group). Additional data from the METIS trial was presented at the 2024 ASCO Annual Meeting showing that patients treated with TTFields also had prolonged quality of life deterioration-free survival (not reached in TTFields group vs 7.7 months in control group).